# Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

> **NCT05429697** · PHASE2,PHASE3 · RECRUITING · sponsor: **SMT bio Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** SMT-NK inj.+Pembrolizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05429697
- **Lead sponsor:** SMT bio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2025-01-08
- **Final completion:** 2026-06-08
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429697, "Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05429697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*